BCRX FY2025 SEC EDGAR DEF 14A #87 of 168 in industry

Biocryst Pharmaceuticals Inc CEO pay ratio

The CEO earned $13.0M in FY2025 against median worker pay of $314,234 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-23
Industry
Chemicals & Pharmaceuticals
Industry rank
#87/168

Data updated August 2026

Subscribe to Biocryst Pharmaceuticals Inc CEO pay filing updates (RSS)

CEO-to-worker pay ratio
41:1
Below Average (Scale: 0–1000:1)
CEO pay
$13.0M
Median worker
$314,234

Answer first

Biocryst Pharmaceuticals Inc's FY2025 CEO total of $13.0M ranks #379 of 1,423 complete filings; its 41:1 pay ratio ranks #1056. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $314,234. Industry placement uses the FY2025 SIC-28 peer cohort (# 87 of 168, 49th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#379
$13.0M of 1,423 FY2025
Ratio rank
#1056
41:1 of 1,423
Industry pct
49th
below the industry median pay ratio

How Biocryst Pharmaceuticals Inc ranks nationally

Biocryst Pharmaceuticals Inc CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$12,951,082 Top 27% higher than 73% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). This entry sits in this band. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Biocryst Pharmaceuticals Inc vs. Chemicals & Pharmaceuticals peers

CEO total pay ($13.0M) against pay ratio (41:1) for Biocryst Pharmaceuticals Inc (marked) and its 3 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both03398027.16796054.210194081.313592108.441.0:141.2:141.5:141.8:142.0:1CEO total payPay ratio (CEO : median worker)Biocryst Pharmaceuticals Inc, CEO total pay: 12951082 · Pay ratio (CEO : median worker): 41:1Biocryst Pharmaceuticals IncEmergent BioSolutions Inc., CEO total pay: 130553 · Pay ratio (CEO : median worker): 41:1Emergent BioSolutions Inc.Regeneron Pharmaceuticals, Inc., CEO total pay: 7313796 · Pay ratio (CEO : median worker): 42:1Regeneron Pharmaceuticals, Inc.Opko Health, Inc., CEO total pay: 1854000 · Pay ratio (CEO : median worker): 42:1Opko Health, Inc.
Biocryst Pharmaceuticals Inc vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Biocryst Pharmaceuticals Inc's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Biocryst Pharmaceuticals Inc

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
41:1
FY2025
vs prior FY
+11:1
from FY2024 30:1
CEO $ YoY
+56%
$13.0M latest
Filings shown
5
FY2021–2025
Biocryst Pharmaceuticals Inc CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $7.1M - $273,522 26:1 -
2022 $7.0M -1.1% $258,689 27:1 +1:1
2023 $4.8M -32% $230,372 21:1 -6:1
2024 $8.3M +74% $274,492 30:1 +9:1
2025 $13.0M +56% $314,234 41:1 +11:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 882796, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
41:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$13.0M
Companies in Industry
168
vs. Industry Median
Below
#87 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Biocryst Pharmaceuticals Inc: MODEST · HEAVY pay ratio

Biocryst Pharmaceuticals Inc's 41:1 ratio ranks #1056 of 1,423 FY2025 complete filings (lower third by ratio). the CEO earned 41× the median employee ($314,234) in FY2025.

Median employee $314,234 (ELITE-MED); MODEST · HEAVY stamps put about 41 median-wage years per CEO year.

CEO Total Pay

$13.0M

FY2025 Summary Compensation, above median

Pay Ratio

41:1

Below typical

Biocryst Pharmaceuticals Inc in the lower-ratio third

Biocryst Pharmaceuticals Inc's 41:1 ratio ranks #1056 of 1,423 FY2025 complete filings (lower third by ratio). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Biocryst Pharmaceuticals Inc's $13.0M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #379 and ratio rank #1056 split - treat 41:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$13.0M
Median Employee Pay
$314,234
Pay Ratio
41:1
Filing Date
2026-04-23

Company Info

Ticker
BCRX
CIK
882796
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 882796, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Biocryst Pharmaceuticals Inc's 41:1 ratio ranks #1056 of 1,423 FY2025 complete filings (lower third by ratio).

Read with Biocryst Pharmaceuticals Inc

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Masco Corp /de/ · HEAVY

ABS(ceo_total_comp) peer at $12.9M (Δ $1K lighter vs Biocryst Pharmaceuticals Inc); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Oshkosh Corp · HEAVY

ABS(ceo_total_comp) peer at $12.9M (Δ $15K lighter vs Biocryst Pharmaceuticals Inc); STEEP · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
AppLovin Corp · HEAVY

ABS(ceo_total_comp) peer at $13.0M (Δ $18K heavier vs Biocryst Pharmaceuticals Inc); MID · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Ingredion Inc · HEAVY

ABS(ceo_total_comp) peer at $12.9M (Δ $30K lighter vs Biocryst Pharmaceuticals Inc); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Emergent BioSolutions Inc. (SIC 28 pole)

Emergent BioSolutions Inc. stamps MODEST · MICRO nearest in-SIC by ABS(pay_ratio) to Biocryst Pharmaceuticals Inc's MODEST filing.
National dual ranks · #379/#1056

Biocryst Pharmaceuticals Inc's FY2025 package sits #379 by CEO dollars and #1056 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Biocryst Pharmaceuticals Inc's MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Biocryst Pharmaceuticals Inc (CIK 882796), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.